To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
New Monoclonal Antibodies to Clostridia GDH
Clostridium difficile associated diarrhea (CDAD) is the leading cause of nosocomial diarrhea. The spread of this bacterium is difficult to control due to its resistant spores that survive on many surfaces.
Thus rapid detection is crucial to its control.
Most rapid tests target the toxins (A & B) produced during the infection. Another diagnostic target is glutamate dehydrogenase (GDH), an enzyme produced and released during bacterial growth.
Studies have shown that adding GDH detection together with toxin detection by EIA or PCR significantly improves assay specificity.
ViroStat has announced the release of three new monoclonal antibodies to Clostridia GDH validated by ELISA. These antibodies represent a new set of tools for rapid detection development.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
